Literature DB >> 25550859

PI3K/AKT signaling pathway plays a role in enhancement of eNOS activity by recombinant human angiotensin converting enzyme 2 in human umbilical vein endothelial cells.

Yan Zhang1, Shi-Jie Wang2, Zhen-Hua Han1, Yong-Qin Li1, Jia-Hong Xue1, Deng-Feng Gao1, Xiao-San Wu1, Cong-Xia Wang1.   

Abstract

The aim of this study was to investigate the effect of PI3K/AKT signaling pathway in the activity of recombinant human angiotensin converting enzyme 2 (rhACE2) promoted the activity of endothelial nitric oxide synthase (eNOS). The human umbilical vein endothelial cells (HUVEC) were cultured in vitro. Then treated with Ang II (1×10(-6) mol/L) for 24 h. The rhACE2 (100 μmol/L) was added and incubated for 5, 10, 15, 30, 60 min respectively which was based on Ang II intervention. The effect of rhACE2 on phosphorylation eNOS level was also observed in the presence of LY294002 (10 μmol/L) (PI3K/AKT inhibitors). Griess reagent method was applied to measure NO contents in cell culture supernatant, RT-PCR to detect the expression of eNOSmRNA in HUVEC, and Western blot to detect the expression of eNOS and phosphorylated eNOS. In Ang II intervention group, NO contents were significantly lower than control group (P < 0.05). Through rhACE2 treatment, the NO contents in cell culture medium and the expression level of phosphorylated eNOS were significantly higher than in Ang II intervention group (P < 0.05), but eNOSmRNA and non-phosphorylated eNOS protein expression level showed no significant difference (P > 0.05). After HUVEC was intervened by PI3K/AKT pathway inhibitor LY294002, the expression level of phosphorylated eNOS was significantly lower than that in the rhACE2 30 min treatment group (P < 0.05). rhACE2 may reduce the activity of Ang II inhibited endothelial cell eNOS, which can be blocked by PI3K/AKT pathway inhibitor LY294002, suggesting PI3K/AKT signaling pathway plays an important role in rhACE2's promotion of the activity of endothelial cell eNOS.

Entities:  

Keywords:  PI3K/AKT signaling pathway; Recombinant human ACE2; nitric oxide synthase

Mesh:

Substances:

Year:  2014        PMID: 25550859      PMCID: PMC4270588     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  20 in total

1.  Angiotensin-(1-7) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways.

Authors:  Walkyria Oliveira Sampaio; Robson Augusto Souza dos Santos; Raphael Faria-Silva; Leonor Tapias da Mata Machado; Ernesto L Schiffrin; Rhian M Touyz
Journal:  Hypertension       Date:  2006-11-20       Impact factor: 10.190

2.  Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction.

Authors:  JiuChang Zhong; Ratnadeep Basu; Danny Guo; Fung L Chow; Simon Byrns; Manfred Schuster; Hans Loibner; Xiu-hua Wang; Josef M Penninger; Zamaneh Kassiri; Gavin Y Oudit
Journal:  Circulation       Date:  2010-08-02       Impact factor: 29.690

3.  Akt-dependent phosphorylation of endothelial nitric-oxide synthase mediates penile erection.

Authors:  K Joseph Hurt; Biljana Musicki; Michael A Palese; Julie K Crone; Robyn E Becker; John L Moriarity; Solomon H Snyder; Arthur L Burnett
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-19       Impact factor: 11.205

4.  Angiotensin (1-7) re-establishes heart cell communication previously impaired by cell swelling: implications for myocardial ischemia.

Authors:  Walmor C De Mello
Journal:  Exp Cell Res       Date:  2014-03-18       Impact factor: 3.905

Review 5.  Recombinant human angiotensin-converting enzyme 2 as a new renin-angiotensin system peptidase for heart failure therapy.

Authors:  Gavin Y Oudit; Josef M Penninger
Journal:  Curr Heart Fail Rep       Date:  2011-09

6.  G-protein-coupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor.

Authors:  Evi Kostenis; Graeme Milligan; Arthur Christopoulos; Carlos F Sanchez-Ferrer; Silvia Heringer-Walther; Patrick M Sexton; Florian Gembardt; Elaine Kellett; Lene Martini; Patrick Vanderheyden; Heinz-Peter Schultheiss; Thomas Walther
Journal:  Circulation       Date:  2005-04-04       Impact factor: 29.690

7.  Angiotensin1-9 antagonises pro-hypertrophic signalling in cardiomyocytes via the angiotensin type 2 receptor.

Authors:  M Flores-Muñoz; N J Smith; C Haggerty; G Milligan; S A Nicklin
Journal:  J Physiol       Date:  2010-12-20       Impact factor: 5.182

8.  Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II-dependent hypertension.

Authors:  Jan Wysocki; Minghao Ye; Eva Rodriguez; Francisco R González-Pacheco; Clara Barrios; Karla Evora; Manfred Schuster; Hans Loibner; K Bridget Brosnihan; Carlos M Ferrario; Josef M Penninger; Daniel Batlle
Journal:  Hypertension       Date:  2009-11-30       Impact factor: 10.190

9.  Enhanced angiotensin converting enzyme 2 regulates the insulin/Akt signalling pathway by blockade of macrophage migration inhibitory factor expression.

Authors:  J-C Zhong; X-Y Yu; Q-X Lin; X-H Li; X-Z Huang; D-Z Xiao; S-G Lin
Journal:  Br J Pharmacol       Date:  2007-10-01       Impact factor: 8.739

10.  ACE2 improves right ventricular function in a pressure overload model.

Authors:  Jennifer A Johnson; James West; Karen B Maynard; Anna R Hemnes
Journal:  PLoS One       Date:  2011-06-10       Impact factor: 3.240

View more
  13 in total

Review 1.  New agents modulating the renin-angiotensin-aldosterone system-Will there be a new therapeutic option?

Authors:  Anna Gromotowicz-Poplawska; Piotr Szoka; Patrycjusz Kolodziejczyk; Karol Kramkowski; Marzena Wojewodzka-Zelezniakowicz; Ewa Chabielska
Journal:  Exp Biol Med (Maywood)       Date:  2016-07-19

2.  Ghrelin protects human umbilical vein endothelial cells against advanced glycation end products-induced apoptosis via NO/cGMP signaling.

Authors:  Pengjie Li; Ying Liu; Ying Xiang; Miao Lin; Jinling Gao
Journal:  Int J Clin Exp Med       Date:  2015-09-15

3.  Protective role of ACE2-Ang-(1-7)-Mas in myocardial fibrosis by downregulating KCa3.1 channel via ERK1/2 pathway.

Authors:  Li-Ping Wang; Su-Jing Fan; Shu-Min Li; Xiao-Jun Wang; Jun-Ling Gao; Xiu-Hong Yang
Journal:  Pflugers Arch       Date:  2016-09-03       Impact factor: 3.657

4.  MicroRNA-615-5p Regulates Angiogenesis and Tissue Repair by Targeting AKT/eNOS (Protein Kinase B/Endothelial Nitric Oxide Synthase) Signaling in Endothelial Cells.

Authors:  Basak Icli; Winona Wu; Denizhan Ozdemir; Hao Li; Henry S Cheng; Stefan Haemmig; Xin Liu; Giorgio Giatsidis; Seyma Nazli Avci; Nathan Lee; Raphael Boesch Guimaraes; Andre Manica; Julio F Marchini; Stein Erik Rynning; Ivar Risnes; Ivana Hollan; Kevin Croce; Xianbin Yang; Dennis P Orgill; Mark W Feinberg
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-05-16       Impact factor: 8.311

5.  Modulatory role of garlicin in migration and invasion of intrahepatic cholangiocarcinoma via PI3K/AKT pathway.

Authors:  Kun Xie; Jianze Nian; Xingyang Zhu; Xiaoping Geng; Fubao Liu
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

6.  Formononetin induces vasorelaxation in rat thoracic aorta via regulation of the PI3K/PTEN/Akt signaling pathway.

Authors:  Teng Li; Yuanyuan Zhong; Tao Tang; Jiekun Luo; Hanjin Cui; Rong Fan; Yang Wang; Dongsheng Wang
Journal:  Drug Des Devel Ther       Date:  2018-11-01       Impact factor: 4.162

7.  Anti-Hypertensive Activity of Novel Peptides Identified from Olive Flounder (Paralichthys olivaceus) Surimi.

Authors:  Jae-Young Oh; Jun-Geon Je; Hyo-Geun Lee; Eun-A Kim; Sang In Kang; Jung-Suck Lee; You-Jin Jeon
Journal:  Foods       Date:  2020-05-18

8.  Isoferulic acid inhibits human leukemia cell growth through induction of G2/M‑phase arrest and inhibition of Akt/mTOR signaling.

Authors:  Zhiguo Long; Guangjia Feng; Na Zhao; Lei Wu; Hongbo Zhu
Journal:  Mol Med Rep       Date:  2020-01-09       Impact factor: 2.952

9.  Downregulation of CD147 induces malignant melanoma cell apoptosis via the regulation of IGFBP2 expression.

Authors:  Shuang Zhao; Lisha Wu; Yehong Kuang; Juan Su; Zhongling Luo; Yan Wang; Jinmao Li; Jianglin Zhang; Wangqing Chen; Fangfang Li; Yijing He; Juan Tao; Jianda Zhou; Xiaowei Xu; Cong Peng; Xiang Chen
Journal:  Int J Oncol       Date:  2018-10-01       Impact factor: 5.650

10.  Rosuvastatin protects against oxidized low‑density lipoprotein‑induced endothelial cell injury of atherosclerosis in vitro.

Authors:  Jianan Geng; Huali Xu; Xiaofeng Yu; Guoliang Xu; Hongyan Cao; Guangzhu Lin; Dayun Sui
Journal:  Mol Med Rep       Date:  2018-11-19       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.